SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin.

Stephan DobnerBenedikt BernhardBabken AsatryanStephan WindeckerStefan StorteckyThomas PilgrimChristoph GräniLukas Hunziker

Published in: ESC heart failure (2022)

In tafamidis-treated ATTR-CM patients, initiation of dapagliflozin was well tolerated. The efficacy of SGLT2i therapy in patients with ATTR-CM needs to be studied in randomized controlled trials.

Keyphrases

newly diagnosed
randomized controlled trial
end stage renal disease
ejection fraction
heart failure
prognostic factors
clinical trial
patient reported outcomes
mesenchymal stem cells
study protocol
atrial fibrillation
patient reported